Matches in Nanopublications for { ?s ?p "DDI between Lovastatin and Carbamazepine - Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of lovastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if carbamazepine is initiated, discontinued or dose changed. [drugbank_resource:DB00227_DB00564]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00227_DB00564 label "DDI between Lovastatin and Carbamazepine - Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of lovastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if carbamazepine is initiated, discontinued or dose changed. [drugbank_resource:DB00227_DB00564]" assertion.